Christopher Fikry MD, MBA

Christopher will join Clario in July 2022, transitioning from his current role as President of the Analytical Services Division at Thermo Fisher Scientific. Christopher previously served as head of Global Lab Services for PPD and held senior executive roles at Novartis and Quest Laboratories. Christopher shares a commitment with biopharmaceutical R&D teams to deliver better healthcare options to patients as well as a commitment to providing high-quality service.

Clario’s Board of Directors warmly welcomes Christopher to Clario, as the company continues to evolve and strengthen its market leadership. In making the announcement, the Board shared, “Christopher’s long experience and commitment to supporting global biopharma and biotech companies, our key customers, in bringing new medicines to patients faster, safer and more cost-effectively is right in line with Clario’s mission. He has demonstrated strong leadership to his teams and customers alike. We would also like to thank Joe for his leadership in successfully bringing together the two predecessor companies, ERT and BioClinica, to form Clario, successfully navigating the pandemic, and creating a strong team and culture in the new organization.”

Christopher will start in his new role in July and Joe will remain CEO during this transitionary period. Following his retirement, Joe will continue to support Clario as a member of the Board of Directors.